Breye Therapeutics ApS: Financial statements 2023
CVR: 40279865
Source: annual report 2023, Danish Business Authority
01/04/2022 – 31/03/2023
Breye Therapeutics ApS (CVR 40279865) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -2,882,747 and a net result of DKK -14,574,884 compared with DKK -780,005 the year before. Equity in the 2023 report amounted to DKK 14,526,382. The solvency ratio was 58.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -2,882,747
- Profit/Loss
- DKK -14,574,884
- Equity
- DKK 14,526,382
- Total Assets
- DKK 24,815,400
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -2.9 mio. | -14.6 mio. | 14.5 mio. | 1 |
| 2022 | - | -674 t. | -780 t. | -752 t. | 1 |
| 2021 | - | -68 t. | -290 t. | 28 t. | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of June 6, 2023, Chiara Rossana Maria Liberati has joined the board of directors of Breye Therapeutics ApS.
As of June 6, 2023, BII Holdings A/S is registered as an owner of Breye Therapeutics ApS with an ownership share of 5%.
As of June 6, 2023, is registered as an owner of Breye Therapeutics ApS with an ownership share of 20%.
About Breye Therapeutics ApS
Breye Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ciana Therapeutics ApS and Visus Therapeutics ApS. The management consists of Ulrik Mouritzen. The board consists of Jimmy Arnold V Van Heusden (chair), Carl Johan Kördel, Chiara Rossana Maria Liberati and Gabriela Burian. The company's owners include Novo Holdings A/S, Visus Holding ApS and BII Holdings A/S. The company has 3 employees (2026). In 2026, the company reported a gross profit of DKK -7,655,438 and a net result of DKK -85,575,302 compared with DKK -89,139,846 the year before. Equity in the 2026 report amounted to DKK -126,213,092.